Systemic markers of the redox balance and apolipoprotein E polymorphism in atherosclerosis: The relevance for an integrated study

Biological Trace Element Research

Volumn 112, Issue 1, 2006, Pages 57-75

  Lopes, Paula A ^a   Napoleão, Patrícia ^a   Pinheiro, Teresa ^b   Ceia, Fátima ^a   Steghens, Jean Paul ^c   Pavão, M Leoner ^d   Santos, M Cristina ^a   Viegas Crespo, Ana M ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b INSTITUTO TECNOLÓGICO E NUCLEAR   (Portugal)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d UNIVERSITY OF THE AZORES   (Portugal)

Author keywords

Antioxidant defenses; Apolipoprotein E; Atherosclerosis; Oxidative damage; Trace elements

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN E; CALCIUM; CARBONYL DERIVATIVE; CERULOPLASMIN; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; POTASSIUM; SUPEROXIDE DISMUTASE; THIOL; TRACE ELEMENT;

ADULT; AGED; ALLELE; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DEMOGRAPHY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OXIDATION REDUCTION STATE;

EID: 33748352972     PISSN: 01634984     EISSN: None     Source Type: Journal    
DOI: 10.1385/BTER:112:1:57     Document Type: Article

References (84)

1. B. Frei, On the role of vitamin C and other antioxidants in atherogenesis and vascular dysfunction, Proc. Soc. Exp. Biol. Med. 222, 196-204 (1999).
2. J. W. Heinecke, Clinical trials of vitamin E in coronary artery disease: is it time to reconsider the low density oxidation hypothesis? Curr. Atherosclerosis Rep. 5, 83-87 (2003).
3. B. Hennig, M. Toborek, and C. J. McClain, High-energy diets, fatty acids and endothelial cell function: implications for atherosclerosis, J. Am. Coll. Nutr. 20(2), 97-105 (2001).
4. P. Fabbi, G. Ghigliotti, C. Brunelli, et al., Intense lipid peroxidation in premature clinical coronary atherosclerosis is associated with metabolic abnormalities, J. Lab. Clin. Med. 143, 99-105 (2004).
5. A. Munteanu, J. -M. Zingg, and A. Azzi, Anti-atherosclerotic effects of vitamin E: myth or reality?, J. Cell Mol. Med. 8(1), 59-76 (2004).
6. J. E. Eichner, S. T. Dunn, G. Perveen, D. M. Thompson, K. E. Stewart, and B. C. Stroehla, Apolipoprotein E polymorphism and cardiovascular disease: a huge review, Am. J. Epidemiol. 155(6), 487-495 (2002).
7. S. Bhakdi, An hypothesis for the immunopathogenesis of atherosclerosis, Clin. Nephrol. 60, S49-S52 (2003).
8. R. W. Mahley, T. L. Innerarity, S. C. Rall, Jr., and K. H. Weisgraber, Plasma lipoproteins: apolipoprotein structure and function, J. Lipid Res. 25, 1277-1294 (1984).
9. R. W. Mahley, Apolipoprotein E: cholesterol transport protein with expanding role in cell biology, Science 240, 622-630 (1988).
10. L. P. L. Van de Vijver, A. F. M. Kardinnal, D. E. Grobbee, H. M. G. Prince, and G. Van Poppel, Lipoprotein oxidation, antioxidants and cardiovascular risk: epidemiologic evidence, Prostaglandins Leukotrienes Essential Fatty Acids 57, 479-487 (1997).
11. I. Durak, M. Kaçmaz, M. Y. B. Çimen, Ü. Büyükkoçak, and H. S. Öztürk, Blood oxidant/antioxidant status of atherosclerotic patients, Int. J. Cardiol. 77, 293-297 (2001).
12. M. Feki, M. Souissi, E. Mokhtar, et al., Vitamin E and coronary heart disease in Tunisians, Clin. Chem. 46(9), 1401-1405 (2000).
13. S. R. Thomas and R. Stocker, Molecular action of vitamin E in lipoprotein oxidation: implications for atherosclerosis, Free Radical Biol. Med. 28(12), 1795-1805 (2000).
14. S. Ylä-Herttuala, LDL oxidation and atherogenesis, in Natural Antioxidants and Food Quality in Atherosclerosis and Cancer Prevention, J. T. Kumpulainen and J. T. Salonen, eds., The Royal Society of Chemistry, Cambridge, pp. 7-9 (1996).
15. B. P. Yu, Cellular defenses against damage from reactive oxygen species, Physiol. Rev. 74, 139-162 (1994).
16. A. J. C. Slooter, M. L. Bots, L. M. Havekes, et al., Apolipoprotein E and carotid artery atherosclerosis: the Rotterdam study, Stroke 32, 1947-1952 (2001).
17. M. H. Shishehbor and S. L. Hazen, Inflammatory and oxidative markers in atherosclerosis: relationship to outcome, Curr. Atherosclerosis Rep. 6, 243-250 (2004).
18. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: executive summary, Am. J. Clin. Nutr. 68, 899-917 (1998).
19. A.-C. Santos and H. Barros, Prevalence and determinants of obesity in an urban sample of Portuguese adults, Public Health 117, 430-437 (2003).
20. F. C. Ballantyne, R. S. Clarck, H. S. Simpson, and D. Ballantyne, HDL and LDL subfractions in myocardial infarction in control subjects, Metabolism 31, 433-437 (1982).
21. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin. Chem. 18(6), 499-502 (1972).
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Cholesterol in Adults. Executive summary of the third report of the National Cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III), JAMA 285, 2486-2497 (2001).
23. J. Sedlak and R. H. Lindsay, Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent, Anal. Biochem. 25, 192-205 (1968).
24. T. Julianto, K. H. Yuen, and M. Noor, Simple HPLC method for determination of α-tocopherol in human plasma, J. Chromatogr. B. 732(1), 227-231 (1999).
25. J. P. Steghens, A. L. Van Kappel, I. Denis, and C. Collombel, Diaminonaphtalene, a new highly specific reagent for HPLC-UV measurement of total and free malondialdehyde in human plasma or serum, Free Radical Biol. Med. 31(2), 242-249 (2001).
26. G. Peiro, J. Alary, J. P. Cravedi, E. Rathahao, J. P. Steghens, and F. Guéraud, Dihydroxynonene mercapturic acid, a urinary metabolite of 4-hydroxynonenal, as a biomarker of lipid peroxidation, Biofactors 24(1-4), 89-96 (2005).
27. R. D. Levine, D. Garland, C. N. Oliver, et al., Determination of carbonyl content in oxidatively modified proteins, Methods Enzymol. 186, 464-478 (1990).
28. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and A. R. Randall, Protein measurement with the Folin phenol reagent, J. Biol. Chem. 193, 265-275 (1951).
29. M. A. Barreiros, T. Pinheiro, M. F. Araújo, M. M. Costa, M. Palha, and R. C. Silva, Quality assurance of X-ray spectrometry for chemical analysis, Spectrochim. Acta B 56(11), 2095-2106 (2001).
30. J. Versieck, L. Van Ballenberghe, A. De Kesel, et al., Certification of a second-generation biological reference material (freeze-dried human serum) for trace element determinations, Anal. Chim. Acta 204, 63-75 (1998).
31. S. A. Miller, D. D. Dykes, and H. F. Polesky, A simple salting out procedure for extracting DNA from human nucleated cells, Nucleic Acids Res. 16, 1215 (1988).
32. J. E. Hixson and D. T. Vernier, Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I, J. Lipid Res. 31, 545-548 (1990).
33. P. Richard, G. Thomas, M. P. Zulueta, et al., Common and rare genotypes of human apolipoprotein E determined by specific restriction profiles of polymerase chain reaction-amplified DNA, Clin. Chem. 40(1), 24-29 (1994).
34. J. H. Zar, Biostatistical Analysis, 3rd ed., Prentice-Hall International, London (1996).
35. B. G. Tabachnick and L. S. Fidell, Using Multivariate Statistics, Harper Collins College, New York (1996).
36. S. W. Guo and E. A. Thompson, Performing the exact test of Hardy-Weinberg proportion for multiple alleles, Biometrics 48, 361-372 (1992).
37. L. Braeckman, D. De Bacquer, M. Rosseneu, and G. De Backer, Apolipoprotein E polymorphism in middle-aged Belgian men: phenotype distribution and relation to serum lipids and lipoproteins, Atherosclerosis 120, 67-73 (1996).
38. H. S. Pedersen, G. Mulvad, W. P. Newman, and D. A. Boudreau, Atherosclerosis in coronary arteries and aorta among Greenlanders: an autopsy study, Atherosclerosis 170, 93-103 (2003).
39. D. Yucel, S. Aydogdu, S. Cehreli, et al., Increased oxidative stress in dilated cardiomyopathic heart failure, Clin. Chem. 44, 148-154 (1998).
40. T. Fukai, R. J. Folz, U. Landmesser, and D. G. Harrison, Extracellular superoxide dismutase and cardiovascular disease, Cardiovasc. Res. 55, 239-249 (2002).
41. J. M. C. Gutteridge, Lipid peroxidation and antioxidants as biomarkers of tissue damage, Clin. Chem. 41(12 Pt. 2), 1819-1828 (1995).
42. M. Piorunska-Stolzmann, M. Iskra, and W. Majewski, The activity of cholesterol esterase and ceruloplasmin are inversely related in the serum of men with atherosclerosis obliterans, Med. Sci. Monit. 7(5), 940-945 (2001).
43. D. Lapenna, S. de Gioia, G. Ciofani, et al., Glutathione-related antioxidant defenses in human atherosclerotic plaques, Circulation 97, 1930-1934 (1998).
44. T. Weinbrenner, M. Cladellas, M. I. Covas, et al., and the SOLOS Study Investigators, High oxidative stress in patients with stable coronary heart disease, Atherosclerosis 168, 99-106 (2003).
45. R. S. Rosenson, Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities, Atherosclerosis 173, 1-12 (2004).
46. C. K. Sen and L. Packer, Thiol homeostasis and supplements in physical exercise, Am. J. Clin. Nutr. 72, 653S-669S (2000).
47. P. Tosukhowong, S. Sangwatanaroj, S. Jatuporn, et al., The correlation between markers of oxidative stress and risk factors of coronary artery disease in Thai patients, Clin. Hemorheol. Microcirc. 29(3-4), 321-329 (2003).
48. N. K. Özer and A. Azzi, Effect of vitamin E on the development of atherosclerosis, Toxicology 148, 179-185 (2000).
49. R. Brigelius-Flohé, F. J. Kelly, J. T. Salonen, J. Neuzil, J.-M. Zingg, and A. Azzi, The European perspective on vitamin E: current knowledge and future research, Am. J. Clin. Nutr. 76, 703-716 (2002).
50. C. Schneider, Chemistry and biology of vitamin E, Mol. Nutr. Food Res. 49, 7-30 (2005).
51. P. A. Lopes, M. C. Santos, L. Vicente, and A. M. Viegas-Crespo, Effect of cigarette smoking on serum a-tocopherol and the lipid profile in healthy humans, Clin. Chim. Acta 348(1-2), 49-55 (2004).
52. K. Miwa, S. Okinaga, and M. Fujita, Low serum a-tocopherol concentrations in subjects with various coronary risk factors, Circ. J. 68, 542-546 (2004).
53. C. Sánchez-Moreno, J. F. Dashe, T. Scott, D. Thaler, M. F. Folstein, and A. Martin, Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative markers after stroke, Stroke 35, 163-168 (2004).
54. L. Tamer, N. Sucu, G. Polat, et al., Decreased serum total antioxidant status and erythrocyte-reduced glutathione levels are associated with increased serum malondialdehyde in atherosclerotic patients, Arch. Med. Res. 33(3), 257-260 (2002).
55. J. Renke, S. Popadiuk, M. Korzon, B. Bugajczyk, and M. Wozniak, Protein carbonyl groups' content as a useful clinical marker of antioxidant barrier impairment in plasma of children with juvenile chronic arthritis, Free Radical Biol. Med. 29(2), 101-104 (2000).
56. T. Miyata, R. Inagi, K. Asahi, et al., Generation of protein carbonyls by glycoxidation and lipoxidation reactions with autoxidation products of ascorbic acid and polyunsaturated fatty acids, FEBS Lett. 437, 24-28 (1998).
57. P. Mecocci, M. C. Polidori, L. Troiano, et al., Plasma antioxidants and longevity: a study on healthy centenarians, Free Radical Biol. Med. 28(8), 1243-1248 (2000).
58. Ü. Mutlu-Türkoglu, E. Ilhan, S. Öztezcan, A. Kuru, G. Aykaç-Toker, and M. Uysal, Age-related increases in plasma malondialdehyde and protein carbonyl levels and lymphocyte DNA damage in elderly subjects, Clin. Biochem. 36, 397-400 (2003).
59. 2+-activated K+ channels by oxidized LDL and its contribution to endothelial production, Cardiovasc. Res. 60, 626-634 (2003).
60. C. Mazière, P. Morlière, Z. Massy, et al., Oxidized low-density lipoprotein elicits an intracellular calcium rise and increases the binding activity of the transcription factor NFAT, Free Radical Biol. Med. 38, 472-480 (2005).
61. P. L. Fox, B. Mazumder, E. Ehrenwald, and C. K. Mukhopadhyay, Ceruloplasmin and cardiovascular disease, Free Radical Biol. Med. 28(12), 1735-1744 (2000).
62. L. -Y. Chau, Iron and atherosclerosis, Proc. Natl. Sci. Counc. ROC (B) 24(4), 151-155 (2000).
63. M. C. Corti, M. Gaziano, and C. H. Hennekens, Iron status and risk of cardiovascular disease, Ann. Epidemiol. 7(1), 62-68 (1997).
64. C. Beaumont, Mécanismes moléculaires de l'homéostasie du fer, Med. Sci. (Paris) 20(1), 68-72 (2004).
65. K. Klipstein-Grobusch, D. E. Grobbee, J. F. Koster, et al., Serum caeruloplasmin as a coronary risk factor in the elderly: the Rotterdam Study, Br. J. Nutr. 81, 139-144 (1999).
66. M. Iskra and W. Majewski, Copper and zinc concentrations and the activities of ceruloplasmin and superoxide dismutase in atherosclerosis obliterans, Biol. Trace Element Res. 73(1), 55-65 (2000).
67. B. Hennig, P. Meerarani, M. Toborek, and C. J. McClain, Antioxidant-like properties of zinc in activated endothelial cells, J. Am. Coll. Nutr. 18(2), 152-158 (1999).
68. P. Evans and B. Halliwell, Micronutrients: oxidant/antioxidant status, Br. J. Nutr. 85(Suppl. 2), 67-74 (2001).
69. G. H. Lyons, G. J. Judson, J. C. R. Stangoulis, L. T. Palmer, J. A. Jones, and R. D. Graham, Trends in selenium status of South Australians, Med. J. Aust. 180, 383-386 (2004).
70. P. A. Lopes, M. C. Santos, L. Vicente, et al., Trace element status (Se, Cu, Zn) in healthy Portuguese subjects of Lisbon population: a reference study, Biol. Trace Element Res. 101, 1-17 (2004).
71. V. Ducros, F. Laporte, N. Belin, A. David, and A. Favier, Selenium determination in human plasma lipoprotein fractions by mass spectrometry analysis, J. Inorg. Biochem. 81(1-2), 105-109 (2000).
72. J. T. Salonen, G. Alfthan, J. Pikkarainen, J. K. Huttunen, and P. Puska, Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study, Lancet 52, 175-179 (1982).
73. J. Nève and Y. Palmieri, First symposium on human health related aspects of selenium research in Europe, J. Trace Elements Med. Biol. 14, 116-121 (2000).
74. M. R. Kafai and V. Ganji, Sex, age, geographical location, smoking, and alcohol consumption influence serum selenium concentrations in the USA: third National Health and Nutrition Examination Survey, 1988-1994, J. Trace Elements Med. Biol. 17(1), 13-18 (2003).
75. M. G. Andreassi, Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage, Mutat. Res. 543, 67-86 (2003).
76. D. A. Boudreau, W. D. Scheer, G. T. Malcom, G. Mulvad, H. S. Pederson, and E. Jul, Apolipoprotein E and atherosclerosis in Greenland Inuit, Atherosclerosis 145, 207-219 (1999).
77. S. R. Srinivasan, C. Ehnholm, A. Elkasabany, and G. S. Berenson, Apolipoprotein E polymorphism modulates the association between obesity and dyslipidemias during young adulthood: the Bogalusa Heart Study, Metabolism 50(6), 696-702 (2001).
78. G. M. Novaro, R. Sachar, G. L. Pearce, D. L. Sprecher, and B. P. Griffin, Association between apolipoprotein E alleles and calcific vascular heart disease, Circulation 108, 1804-1808 (2003).
79. C. Ehnholm, M. Lukka, T. Kuusi, E. Nikkilä, and G. Utermann, Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations, J. Lipid Res. 27, 227-235 (1986).
80. T. B. Shea, E. Rogers, D. Ashline, D. Ortiz, and M.-S. Sheu, Apolipoprotein E deficiency promotes increased oxidative stress and compensatory increases in antioxidants in brain tissue, Free Radical Biol. Med. 33(8), 1115-1120 (2002).
81. J. H. Stengard, K. E. Zerba, J. Pekkanen, C. Ehnholm, A. Nissinen, and C. F. Sing, Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men, Circulation 91, 265-269 (1995).
82. J. H. Stengard, J. Pekkanen, C. Ehnholm, A. Nissinen, and C. F. Sing, Genotypes with the apolipoprotein e4 allele are predictors of coronary heart disease mortality in a longitudinal study of elderly Finnish men, Hum. Genet. 97, 677-684 (1996).
83. I. Pirim, F. Polat, E. Akarsu, Y. N. Sahin, and E. Bozkurt, Apolipoprotein-E genotyping in patients with coronary heart disease, Turk. J. Med. Sci. 31, 229-233 (2001).
84. M. L. Sentman, T. Brännström, S. Westerlund, et al., Extracellular superoxide dismutase deficiency and atherosclerosis in mice, Arteriosclerosis Thromb. Vasc. Biol. 21, 1477-1482 (2001).